Clinical Trials Logo

Clinical Trial Summary

To determine the role of initial pars plana vitrectomy in the management of postoperative bacterial endophthalmitis.

To determine the role of intravenous antibiotics in the management of bacterial endophthalmitis.

To determine which factors, other than treatment, predict outcome in postoperative bacterial endophthalmitis.


Clinical Trial Description

Endophthalmitis is a serious ocular infection that can result in blindness. Approximately 70 percent of cases occur as a direct complication of intraocular surgery. Current management requires culture of intraocular contents and administration of an antibiotic. Vitrectomy surgery, which may help to manage endophthalmitis by removing infecting organisms and their toxins, has been shown to be of value in various animal models of endophthalmitis. However, human studies have not shown an advantage to vitrectomy with intraocular antibiotics compared with intraocular antibiotics alone.

In all large comparison studies to date, eyes with the worst initial presentations were the ones selected for vitrectomy. Because of the selection bias involved in determining which cases received vitrectomy, existing clinical information on the efficacy of the procedure for treating endophthalmitis is inconclusive. Determining the role of initial vitrectomy and the benefit or lack of benefit to certain subgroups of patients will help the clinician in the management of endophthalmitis.

In addition, although systemic antibiotics have long been used in the management of endophthalmitis, there has been little evidence to support their efficacy, but there have been many reports of toxic systemic effects. In view of this, the role of systemic antibiotics in the management of endophthalmitis will be assessed.

Endophthalmitis Vitrectomy Study (EVS) patients were randomized to one of two standard treatment strategies for the management of bacterial endophthalmitis. Eyes received either (1) initial pars plana vitrectomy with intravitreal antibiotics, followed by retap and reinjection at 36-60 hours for eyes that did poorly as defined in the study or (2) initial anterior chamber and vitreous tap/biopsy with injection of intravitreal antibiotics, followed by vitrectomy and reinjection at 36-60 hours in eyes doing poorly. In addition, all eyes were randomized to either treatment or no treatment with intravenous antibiotics.

Study end points were visual acuity and clarity of ocular media, the latter assessed both clinically and photographically. Each patient's initial end point assessment occurred at 3 months, after which procedures to improve vision, such as late vitrectomy for nonclearing ocular media, were an option. The final outcome assessment occurred at 9 months. Multiple centers cooperated by enrolling 420 eyes during the 42-month recruitment period. ;


Study Design

Allocation: Randomized, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00000130
Study type Interventional
Source National Eye Institute (NEI)
Contact
Status Completed
Phase Phase 3
Start date February 1990
Completion date January 1995

See also
  Status Clinical Trial Phase
Recruiting NCT04214821 - The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% Phase 1/Phase 2
Completed NCT00461656 - Povidone-iodine Antisepsis for Strabismus Surgery Phase 4
Completed NCT00136344 - Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery N/A
Completed NCT04568213 - Hypochlorous Acid Disinfection Prior to Cataract Surgery Phase 3
Terminated NCT01496794 - Endophthalmitis Cultures N/A
Completed NCT00406913 - Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery N/A
Recruiting NCT05079854 - Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis Phase 4
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Recruiting NCT02810587 - Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics N/A
Completed NCT00398658 - Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis Phase 4
Recruiting NCT04035369 - Endophthalmitis Post Intravitreal Injections N/A
Not yet recruiting NCT03420820 - Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection N/A
Recruiting NCT06268561 - Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
Withdrawn NCT00335231 - Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery N/A
Not yet recruiting NCT03244072 - Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Phase 2/Phase 3
Completed NCT01323868 - Endogenous Endophthalmitis in the Inpatient Setting N/A
Completed NCT03363295 - Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis Phase 4
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Terminated NCT02770729 - Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis. Phase 3
Not yet recruiting NCT02324166 - Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain Phase 4